Improving Hepatitis B and C Care Cascades; Focus on Increased Testing and Diagnosis (CDC-RFA-PS17-1702)

Period Length: 4 years

Funding is expected to be approximately $5.7M each year

This program will increase the number of persons living with hepatitis B and hepatitis C infection that are tested for these infections, made aware of their infection, and linked to recommended care and treatment services.

CDC has awarded funding to 46 U.S. states, three cities, and the District of Columbia:

  • Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, Nevada, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming
  • Chicago, New York City, Philadelphia
  • Washington, DC

Through this cooperative agreement, state and local health departments will:

  • Incorporate viral hepatitis prevention activities into existing public health, clinical care, and community settings.
  • Educate the public, partners, and stakeholders on relevant policies including state-mandated hepatitis B and hepatitis C reporting, and public/private insurance reimbursement for recommended testing and treatment.
  • Work with state agencies to improve hepatitis B and hepatitis C testing, detection, and linkage to care and treatment in all settings.
  • Monitor and evaluate how policies impact testing, care, and treatment of hepatitis B and hepatitis C.

Supplement: CDC-RFA-PS17-17020301SUPP19.